# Intervacc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/intervacc). ## Overview Intervacc is a Swedish animal-health company that develops and commercializes vaccines for infectious diseases in horses and livestock. Its business is built around a proprietary recombinant fusion-protein technology platform and includes vaccine development, veterinary medicine distribution, and diagnostic services through its group companies. ## Products & services • Strangvac vaccine for equine strangles • INV274 vaccine project for Streptococcus suis • Veterinary medicine distribution in Scandinavia • Veterinary bacteriology diagnostic services • Recombinant fusion-protein vaccine platform - **Vaccines for horses** (60%) — Vaccines and related development for equine infectious diseases, centered on Strangvac. - **Veterinary medicines distribution** (20%) — Distribution of veterinary medicines in the Scandinavian market through Nordvacc Läkemedel AB. - **Veterinary diagnostics** (10%) — Laboratory diagnostic services in veterinary bacteriology through Mybac-Vettech AB. - **Pipeline vaccines and R&D** (10%) — Development-stage vaccine projects for pig and other animal infections. - Strangvac vaccine for equine strangles - INV274 vaccine project for Streptococcus suis - Veterinary medicine distribution in Scandinavia - Veterinary bacteriology diagnostic services - Recombinant fusion-protein vaccine platform ## Customers Intervacc sells to veterinarians, horse owners, equine practices, and animal-health distributors that serve the horse market. Its development pipeline also targets pig producers and the broader livestock health ecosystem, where disease prevention and reduced antibiotic use are important buying motives. - **Equine veterinarians and clinics** (primary) — Buy or recommend Strangvac to prevent equine strangles in horse populations. - **Horse owners and stable operators** (primary) — Use vaccines to reduce outbreak risk and protect horse herds. - **Veterinary medicine distributors** (secondary) — Purchase and distribute veterinary medicines in Scandinavian markets. - **Pig producers and veterinarians** (emerging) — Potential future buyers of Streptococcus suis vaccines to reduce disease losses. - **Diagnostic laboratory customers** (secondary) — Use bacteriology testing services for veterinary diagnosis and monitoring. - Veterinarians treating horses and managing strangles prevention - Horse owners and stable operators seeking disease protection - Animal-health distributors serving Scandinavian veterinary markets - Pig producers and veterinarians focused on Streptococcus suis prevention - Dairy and livestock stakeholders interested in future vaccine projects ## Geography Intervacc is headquartered in Sweden and operates through a Scandinavian distribution and diagnostics footprint. Its lead vaccine, Strangvac, is available in several important European markets, and the company is also pursuing access to the U.S. market through USDA-related approval work. - **Sweden** (35%) — Headquarters and core operating base - **Europe** (50%) — Commercial markets for Strangvac and broader European presence - **North America** (15%) — Target market for future Strangvac licensing and sales - Headquartered in Sweden with group operations in Scandinavia - Strangvac is sold in several important European markets - Europe is the core commercial geography for the lead vaccine - The U.S. is a regulatory expansion target for Strangvac - Pipeline projects address global horse and pig markets ## Strategy Intervacc’s strategy is to build a commercial animal-health franchise around Strangvac while advancing follow-on vaccine projects for other bacterial infections. The company is also working to broaden geographic reach, especially by pursuing U.S. licensing, and to deepen its platform-based pipeline across horses, pigs, and dairy cattle. - **Commercialize Strangvac in core horse markets** (short-term) — The lead product anchors current revenue potential and brand recognition. - **Obtain U.S. market access** (medium-term) — The U.S. horse market expands the addressable customer base for Strangvac. - **Advance the Streptococcus suis pipeline** (medium-term) — A second successful vaccine would diversify the product base and reduce dependence on one asset. - **Scale the recombinant fusion-protein platform** (long-term) — The same platform can support multiple animal-health indications and improve pipeline efficiency. - Expand Strangvac commercialization in Europe - Pursue U.S. licensing through USDA approval - Advance Streptococcus suis vaccine development - Leverage one technology platform across multiple diseases - Use partnerships and external manufacturing to scale ## Risks Intervacc is exposed to commercialization risk because a large share of its value depends on Strangvac’s market adoption and execution. As a research-driven animal-health company, it also faces financing, manufacturing, regulatory, and key-person risks that are common in vaccine development but especially important when production is outsourced and the pipeline is still concentrated. - **Dependence on Strangvac commercialization** [high] — Only one vaccine project is currently launched and able to generate revenue, so underperformance would affect valuation and forecasts. - **Financing risk** [high] — Drug R&D is capital intensive and the company may need external funding to support operations and development. - **Manufacturing disruption** [high] — The company relies on contracted external manufacturers for vaccine components, filling, and packaging. - **Regulatory approval risk** [medium] — U.S. commercialization requires USDA-related approval, which can be lengthy and uncertain. - **Key employee dependence** [medium] — Loss of senior executives or technical staff could slow development and commercial execution. - Strangvac commercialization risk is concentrated in one lead product - Financing risk is high because R&D consumes cash before scale-up - External manufacturing creates supply and quality-control exposure - Regulatory approval can delay U.S. market entry - Loss of key employees could disrupt development and commercialization ## Accounting Intervacc reports under Swedish K3 rules and presents amounts in TSEK, so investors should watch how development spending, external manufacturing costs, and project-related grants flow through the income statement. Because the business is still concentrated in a small number of products and projects, judgments around capitalization, impairment, and the recoverability of asset values can materially affect reported results. - **K3 accounting framework** — Reported earnings and balance sheet values - **Impairment and recoverability judgments** — Intangible assets and forecast assumptions - **R&D expense timing** — Operating result and comparability - **External manufacturing and launch costs** — Quarterly expense volatility - **Grant accounting** — Net R&D cost presentation - K3 reporting affects presentation and measurement of development items - TSEK reporting can obscure small quarter-to-quarter changes - Project concentration raises impairment and recoverability judgments - External manufacturing and launch timing can shift expense recognition - Grant-funded R&D may affect how project costs are netted or disclosed --- *Last updated: 2026-08-11T04:04:53.498979+00:00*